These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 2667349

  • 1. Guidelines for recombinant human erythropoietin therapy.
    Eschbach JW, Adamson JW.
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
    [Abstract] [Full Text] [Related]

  • 2. Who should receive recombinant human erythropoietin?
    Van Stone JC.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [Abstract] [Full Text] [Related]

  • 3. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [Abstract] [Full Text] [Related]

  • 4. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB.
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [Abstract] [Full Text] [Related]

  • 5. Practical considerations of recombinant human erythropoietin therapy.
    Paganini EP, Latham D, Abdulhadi M.
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [Abstract] [Full Text] [Related]

  • 7. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [Abstract] [Full Text] [Related]

  • 8. Resistance to recombinant human erythropoietin therapy: a real clinical entity?
    Stivelman JC.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):8-11. PubMed ID: 2669085
    [Abstract] [Full Text] [Related]

  • 9. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [Abstract] [Full Text] [Related]

  • 10. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG.
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [Abstract] [Full Text] [Related]

  • 11. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP, Abels RI, McNeill MV, Sullivan DJ.
    Arch Intern Med; 1993 Dec 13; 153(23):2669-75. PubMed ID: 8250662
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA, Verberckmoes R, Michielsen P, Koene RA.
    Nephrol Dial Transplant; 1989 Dec 13; 4(9):782-6. PubMed ID: 2516609
    [Abstract] [Full Text] [Related]

  • 13. [Effectiveness of recombinant human erythropoietin in the treatment of transfusion-dependent anemia in patients on chronic dialysis].
    Graf H, Mayer G, Cada EM, Thum J, Stummvoll HK.
    Wien Klin Wochenschr; 1987 Dec 18; 99(24):855-9. PubMed ID: 3439185
    [Abstract] [Full Text] [Related]

  • 14. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J, Koch KM.
    Clin Nephrol; 1995 Nov 18; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [Abstract] [Full Text] [Related]

  • 15. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD, James KM, Levy JK, Browne JK, Miller A, Lobingier RT, Egrie JC.
    J Am Vet Med Assoc; 1998 Feb 15; 212(4):521-8. PubMed ID: 9491159
    [Abstract] [Full Text] [Related]

  • 16. Review of patients' responses to epoetin alfa therapy.
    Krantz SB.
    Pharmacotherapy; 1990 Feb 15; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [Abstract] [Full Text] [Related]

  • 17. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P, Andre JL, Treize G, Leroy B.
    Arch Fr Pediatr; 1993 Mar 15; 50(3):201-8. PubMed ID: 8338412
    [Abstract] [Full Text] [Related]

  • 18. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
    Nissenson AR.
    Semin Nephrol; 1989 Mar 15; 9(1 Suppl 2):25-31. PubMed ID: 2669083
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ, Carey P, Johnson CA.
    Am J Hosp Pharm; 1992 Jun 15; 49(6):1451-4. PubMed ID: 1529988
    [Abstract] [Full Text] [Related]

  • 20. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M, Dalva I, Yazicioğlu A, Akbay E, Cetin S.
    Int Urol Nephrol; 1993 Jun 15; 25(2):197-203. PubMed ID: 8365853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.